Study of Blood Levels of Direct Oral Anticoagulants in Chinese Patients With Atrial Fibrillation During Temporary Medication Pause for Medical Procedures

What this Trial Is About

Researchers are investigating the levels of direct oral anticoagulants DOACs in Chinese patients with non-valvular atrial fibrillation NVAF who require temporary interruption of these medications before elective medical procedures. The study aims to understand ethnic-specific pharmacokinetic and pharmacogenomic profiles of DOACs, as current guidelines based on Western populations may not fully apply to Asian patients. This research hopes to improve periprocedural management and acute stroke care strategies in this growing patient population. Participants taking one of four DOACsapixaban, dabigatran, edoxaban, or rivaroxabanwho need to stop their medication for at least 48 hours before procedures such as colonoscopy or cardiac catheterization will be enrolled. Blood samples will be collected at peak, trough, 24 hours, and 48 hours after stopping DOACs to measure drug levels and conduct pharmacogenomic studies. The study also records detailed patient information including demographics, medical history, concurrent medications, and clinical assessments. During the study, participants will undergo various blood tests including specific coagulation assays, liquid chromatography-mass spectrometry, and DNA microarray analysis. Researchers will monitor participants neurological and hemodynamic status closely, resuming DOACs once it is safe to do so. Follow-up visits will occur 30 days after the procedure to assess any bleeding or thromboembolic events. This observational study will provide valuable data on DOAC management and safety in Chinese patients.

DOAC in Chinese Patients With Atrial Fibrillation